Abstract
The report covers a forecast and an analysis of the Parkinson’s disease therapeutics market on a global and regional level. The study provides historical data from 2016 to 2018 along with a forecast from 2019 to 2025 based on revenue (USD Billion). The study includes drivers and restraints of the Parkinson’s disease therapeutics market along with their impact on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the Parkinson’s disease therapeutics market on a global level.
In order to give the users of this report a comprehensive view of the Parkinson’s disease therapeutics market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.
The report provides company market share analysis to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new technology launch, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the market on a global and regional basis. Moreover, the study covers price trend analysis and product portfolio of various companies according to regions.
The study provides a decisive view of the Parkinson’s disease therapeutics market by segmenting it based on drug class, route of administration, distribution channel, and region. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2025. The regional segment includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa with its further classification into major countries.
Some players of the global Parkinson’s disease therapeutics market are Teva Pharmaceutical Industries, STADA Arzneimittel, Impax Laboratories, Novartis, F. Hoffmann-La Roche, Merck & Co., UCB Inc., GlaxoSmithKline, AbbVie, and Valeant Pharmaceuticals International.
This report segments the global Parkinson’s disease therapeutics market into:
Global Parkinson’s Disease Therapeutics Market: Drug Class Analysis
Levodopa Combination
Dopamine Agonists
Monoamine Oxidase B (Mao-B) Inhibitors
Anticholinergic Drugs
Catechol-O-Methyltransferase (COMT) Inhibitors
Others
Global Parkinson’s Disease Therapeutics Market: Route of Administration Analysis
Oral
Transdermal
Subcutaneous
Intestinal Infusion
Global Parkinson’s Disease Therapeutics Market: Distribution Channel Analysis
Hospital Pharmacy
Retail Pharmacy
Online Sales
Global Parkinson’s Disease Therapeutics Market: Regional Analysis
North America
The U.S.
Europe
UK
France
Germany
Asia Pacific
China
Japan
India
Latin America
Brazil
Middle East and Africa